Silver nanoparticles: synthesis, properties, toxicology, applications and perspectives

Choose your preferred view mode

Paint the Web with CSS - Eva Lettner @ WeAreDevelopers Conference 2017

2008 antibacterial development conferences

[GOOGLEFREETEXTUNIQ-5-7acute gout arthritis]

Collaborating in more than countries. By clicking on a link below, you may enter a different part of this website, or a website outside of Janssen. These sections or websites are governed by their own Legal and Privacy Policies. We share an overarching mission: Mathai practices source-agonistic innovation, leading one of the most powerful, 2008 antibacterial development conferences, creative and productive teams of professionals in the industry, and greatly valuing partnerships of numerous types with the Life Sciences ecosystem including small and large life science companies, technology companies, universities, venture groups and government.

He focuses energy at the intersection of profound unmet medical need and actionable 2008 antibacterial development conferences in science and technology to make medicines of unequivocal benefit for humanity, 2008 antibacterial development conferences.

Jointly with his team, he initiated numerous new programs and progressed eight into early clinical development. His talented team of scientists nominated 31 development candidates in 17 years, created four approved products, filed for approval of a fifth and created a pipeline containing many additional development-stage compounds in Inhe and the Theravance Leadership Team separated Theravance into two publicly traded companies: Mathai has more than peer-reviewed publications and patents and serves on various boards and advisory committees.

He received his M. In his global role, he oversees the development process overall, as well as essential analytical capabilities portfolio, statistics, clinical operationsand is accountable for operationalizing and managing the extensive development portfolio. He joined the Janssen Research Foundation in and led the global clinical development of one of the most successful Janssen red and yellow die allergy medicines.

Stef obtained his M. He is a recipient of the Dr. Dash received a B. He subsequently carried out postdoctoral research in natural product synthesis at Northwestern University in Illinois, United States prior to joining GSK. In addition, he has published extensively on a variety of drug discovery topics. In addition, he has been an invited speaker at major scientific conferences.

He leads a global team focused on combining internal and external innovation approaches to discover and develop new solutions for oncologic and hematologic diseases with high unmet medical need. In this role, he was responsible for strategic oversight and execution of the Janssen hematologic malignancy drug discovery and 2008 antibacterial development conferences programs.

Before joining Janssen, Peter was Vice President in both early and late-stage clinical development for another leading pharmaceutical company, where 2008 antibacterial development conferences successfully filed 10 Investigational New Drug IND applications with the United States Federal Drug Administration FDA2008 antibacterial development conferences, played a major role in the global registration of three oncology drugs and led major projects from preclinical discovery through pivotal Phase 3 trials.

Jim has end-to-end research and development responsibility for the Janssen CVM portfolio, including drug discovery, clinical development, and external innovation. Jim joined Janssen in Earlier in his career, James was a faculty member of the Harvard Medical School in Cambridge, Massachusetts with clinical responsibilities in General Endocrinology and Thyroid. Husseini received his B. His work has helped to conceptualize these illnesses as genetically influenced disorders of synaptic and neural plasticity, and has led to the investigation of novel therapeutics for refractory patients, 2008 antibacterial development conferences.

He has also been actively involved in the development of biomarkers to help refine these multifactoral diseases into mechanism-based subcategories to develop targeted therapeutics. In addition to his neuroscience research and biomarker and therapeutics development endeavors, Husseini has also been actively involved in medical and neuroscience education undertakings, and has served as a member of the National Board of Medical Examiners NMBE Behavioral Science Test Committee, the Howard Hughes Medical Institute Research Scholars Program Selection and Advisory Committee and numerous national curriculum committees.

Husseini has published extensively on the type 1 diabetes and infants and cellular neurobiology of severe neuropsychiatric disorders and the development of novel therapeutics. He was editor of Neuropsychopharmacology Reviews: The Next Generation of Progressdeputy editor 2008 antibacterial development conferences Biological Psychiatryassociate editor of the journal Bipolar Disorders and has been a member of the editorial board of numerous journals.

He leads a global team focused on continuously creating and progressing transformational medicines to help fight infectious diseases including influenza, respiratory syncytial virus RSVHIV and hepatitis B. Previously at Pfizer, Inc. He also realized the vitamin b 6 and weight loss of antibacterial macromolecules and the clinical evaluation of novel broad-spectrum antibiotics.

James is committed to exploring new avenues of research in the fight against infectious diseases. In addition to his antiviral expertise, his research has been focused on immuno-oncology and the combination of vaccines, oncolytic viruses and immunomodulators to treat chronic diseases which include various types of cancers.

He holds a Ph. He is a member of the New York Academy of Sciences, the British Society of Immunology and the Is peppermint oil antibacterial Society of Vaccines, and has served on several scientific advisory and company boards. Sanjaya is responsible for leading an organization focused on biotherapeutic research, 2008 antibacterial development conferences, discovery, toxicology, clinical pharmacology and strategic external collaboration.

Sanjaya is an accomplished scientific and business leader with more than 25 years of industry and academic experience. During his tenure, Sanjaya led a global team responsible for building a competitive and productive pre-clinical and clinical biotherapeutics pipeline. He has successfully led the identification of therapeutic targets in the field of immunomodulation and has developed biologic molecules in the fields of immunology, oncology, ophthalmology, cardio-metabolic and infectious disease.

An author of numerous peer-reviewed articles, Sanjaya also is co-author on more than 25 patents. Sanjaya earned a Ph. In this role, he leads an integrated discovery and manufacturing sciences organization that comprises all modalities including small molecules, traditional and non-traditional single molecule biologics, and larger, more complex multicomponent biologics including RNA, viruses and cells.

Rich obtained his Ph. He has published more than 70 scientific articles and publications and he holds several patents. As head of the Global Regulatory Affairs GRA within Janssen Pharma, Karin Van Baelen leads an organization of approximately highly qualified colleagues who foster relationships with Health Authorities around the world and deliver 2008 antibacterial development conferences healthcare solutions to patients. Under her leadership, the GRA organization influences and interprets global nickel plate antibacterial requirements and enables our company to meet those guidelines.

In addition, GRA oversees the development of regulatory strategy for products from all therapeutic areas, as well as the schedule and budget control plan of high-quality, on-time regulatory submissions and approvals. GRA also engages in policy development at national and international levels in the regulatory, 2008 antibacterial development conferences, biotechnology and clinical development arenas.

From toshe led the EMEA Regional Regulatory Affairs team in all regulatory aspects for all therapeutic areas and all operating company regulatory organizations in the region. She also worked with GRA at the Janssen Research Foundation and was responsible for the worldwide registrations of several key products, 2008 antibacterial development conferences, including medications for severe mood disorders and pain.

Karin 2008 antibacterial development conferences her Doctor of Pharmacy Pharm. Johan Van Hoof, M. Johan was actively involved in the development and licensing of a new generation of childhood and adult vaccines in disease areas such as pertussis pediatric combined vaccinesmeningitis, rotaviral diarrhea, hepatitis, flu and HPV. This section of the global Janssen website provides a company overview in several languages. It is not targeted to any specific audience or country.

Click here for country- and region-specific information of interest. Making a Splash for Disease Awareness. Judith Hinton Andrew, Rock Composite Dash DhanakPh.

Global Head, Discovery Sciences. Global Therapeutic Area Head, Oncology. Global Therapeutic Area Head, Neuroscience. Global Therapeutic Head, Infectious Diseases. Global Head, 2008 antibacterial development conferences BioTherapeutics. Karin Van Baelen, Pharm. Head, Global Regulatory Affairs.


2008 antibacterial development conferences